Use of Hyperimmune Immunoglobulin (HIG) in Complex Therapy of Patients with COVID-19

Introduction. Neutralizing antibodies effectively inhibit viral replication and reduce the severity of the disease. With the emergence of new COVID-19 strains, many monoclonal antibody preparations have lost cross-neutralizing activity. COVID-globulin is a highly purified preparation of specific immunoglobulin G against SARS-CoV-2 for intravenous administration, considered as an effective agent in the treatment of COVID-19 [1]. Purpose. Improve the combination therapy of patients with COVID-19 using COVID-globulin based on an analysis of the clinical efficacy and safety of the drug. Materials and methods. A retrospective, open, randomized, single-center study was conducted from 01.01.2022 to 01.31.2023. 117 inpatients with COVID-19 were observed. Patients of the main group (n=57) were administered COVID-globulin intravenously by drip at a dosage of 1 ml/kg of body weight on days 1–18 of the disease. Clinical, laboratory and instrumental parameters of patients were observed and analyzed dynamically. Statistical analysis was performed using IBM SPSS Statistics ver. 26 (IBM; USA). Results. Analysis of the main parameters over time showed: an increase in SpO2 to 96%, a decrease in respiration rate to 20 bpm (p<0.001). In the group of patients who did not receive COVID globulin, a significantly more pronounced degree of lung damage (CT) was revealed in the dynamics of the disease: upon discharge, in patients who received COVID globulin, CT-0 was determined in 70.4% of patients, while in patients who received COVID globulin, CT-0 was detected in 10.5% of patients. In patients who received COVID globulin, a decrease in the level of CRP was noted in dynamics after the administration of 32 mg/l [10–91.75] upon admission and 19 mg/l [13.5–42.25] upon discharge in patients who received COVID globulin (p<0.001). No obvious positive clinical and laboratory dynamics were observed with a single administration of the drug 7 days after the onset of the disease. Conclusions. The results of the study demonstrate the effectiveness and safety of early (before the 7th day of illness) use in patients who received COVID-globulin at a dosage of 1 ml/kg of body weight in the complex therapy of patients with COVID-19. © 2025 Elsevier B.V., All rights reserved.